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Abstract
Purpose
We investigated if programmed death-ligand 1 (PD-L1) expression levels were prognostic
of survival outcomes after intensity-modulated radiation therapy (IMRT) for non-metastatic
nasopharyngeal carcinoma (NPC).
Methods and Materials
104 patients with non-metastatic NPC treated with radical IMRT were investigated for their
PD-L1 expression by immunohistochemistry (IHC) which were correlated with survival end-
points including locoregional failure-free survival (LRFFS), progression-free survival (PFS),
distant metastasis-free survival (DMFS) and overall survival (OS).
Results
After a median follow-up of 7.6 years, 21 (20.2%), 19 (18.3%) and 31 (29.8%) patients suf-
fered from locoregional failure, distant metastases and overall disease progression, respec-
tively, and 31 (29.8%) patients died. Patients whose tumors had PD-L1 IHC 2+ (moderate
to strong membrane staining in 25% of tumor cells) enjoyed longer LRFFS (5-year 100%
vs. 74.4%, Hazard ratio [HR], 0.159, 95% confidence interval [CI], 0.021–0.988; P = 0.042)
and marginally longer PFS (5-year 95.0% vs. 65.2%, HR, 0.351, 95% CI, 0.08–0.999, P =
0.067) compared to those whose tumors had PD-L1 IHC 0 (minimal membrane staining
with PD-L1 in < 5% tumor cells or no staining with PD-L1) or 1+ (minimal to moderate mem-
brane staining with PD-L1 in between 5–24% tumor cells). PD-L1 IHC 2+ was indepen-
dently prognostic of both LRFFS (P = 0.014) and PFS (P = 0.045) in multivariable analyses.
Only induction chemotherapy followed by concurrent chemoradiation was prognostic of
DMFS (P = 0.003) and no prognostic factor for OS was identified.
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Conclusion
PD-L1 expression levels correlated with LRRFS and PFS in non-metastatic NPC treated
with radical IMRT. It may play a role in radiosensitivity for NPC, which should be further con-
firmed in prospective studies using immunotherapy together with IMRT.
Introduction
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in southern China, Hong Kong,
Taiwan and Singapore where there is a strong genetic predisposition [1,2]. The undifferentiated
type (WHO Type 3) is highly associated with Epstein-Barr virus (EBV) which carries a better
prognosis as compared to the keratinizinig squamous carcinoma (WHO Type 1). Radiation
therapy is the mainstay of treatment for non-metastatic NPC especially for early-stage diseases
while concurrent cisplatin-based chemoradiation is indicated for stage III to IVB diseases [3].
Intensity-modulated radiation therapy (IMRT) has been considered the standard radiation
technique for NPC in virtue of its superior tumor coverage and organ sparing from necessary
radiation leading to better locoregional control and reduced toxicities [4–10]. Unlike other
head and neck squamous cell carcinoma in which anti-epidermal growth factor receptor (anti-
EGFR) antibody cetuximab can be effectively combined with radiation therapy as curative
treatment with similar efficacy as chemotherapy for non-metastatic diseases, there has been no
conclusive evidence of targeted therapy combined with radiation therapy which showed com-
parable efficacy as chemotherapy in the same setting [11–14]. Recently, immune checkpoints
and immunotherapy have been extensively studied in an attempt to redirect host anti-tumor
responses to cancer cells [15]. It is well-recognized that cancer cells can evade host immunosur-
veillance by inhibiting functions of cytotoxic T-lymphocytes through the expression of certain
ligands. Blockage of these ligands or their receptors by specific targeted drugs may result in
reactivation of host immune responses thus enhancing anti-tumor effects. Programmed death-
1 (PD-1) is an immune checkpoint on the surface of T-lymphocytes [16]. The corresponding
ligand called programmed death-ligand 1 (PD-L1) is moderately to strongly expressed in vari-
ous types of cancer including melanoma, non-small-cell lung cancer and head and neck can-
cers. Unlike EGFR in which high expression is associated with poor response to radiation
therapy in head and neck cancers [17,18], PD-L1 expression has not been found to correlate
with treatment outcomes after radiation therapy for head and neck cancers including NPC.
Based on the above, we investigated the correlation of expression levels of PD-L1 in tumor cells
and tumor infiltrating lymphocytes (TIL) with survival outcomes in patients with non-meta-
static NPC treated with IMRT.
Methods and Materials
Patient eligibility and pretreatment investigations
Prior approval from local institutional review board (Institutional Review Board of the Univer-
sity of Hong Kong/Hospital Authority Hong Kong West Cluster, approval number UW 15–
222) was obtained before study commencement. All clinical investigations were conducted
according to the principles of Declaration of Helsinki. All patients provided written informed
consent before study recruitment. Patients with previously untreated non-metastatic NPC who
were treated with IMRT between 2005 and 2009 were reviewed from a prospectively collected
database. Formalin-fixed paraffin-embedded (FFPE) archived nasopharyngeal tumor samples
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were retrieved for PD-L1 expression analysis as described below. Pretreatment investigations
and workup included blood tests for serum hematology, biochemistry, hepatitis B serology,
serology for antibodies against EBV viral capsid antigen (VCA) and early antigen (EA), fabrica-
tion of customized thermoplastic head and neck cast for the following contrast-enhanced com-
puted tomography (CT) scanning of the head and neck region in IMRT treatment position
with 3mm slice thickness co-registered with the T1, T2 and gadolinium-enhanced magnetic
resonance images (MRI) of the head and neck region acquired by a 3-tesla scanner for subse-
quent target and organs-at-risk (OAR) delineation and subsequent IMRT treatment planning
and optimization and contrast-enhanced CT scan of the thorax and abdomen to rule out dis-
tant metastases. Patients who suffered from stage I to small stage II diseases received IMRT
alone while those with bulky stage II disease received concurrent chemoradiation with cisplatin
100mg/m2 on day 1, 22 and 43 of IMRT. Patients who suffered from stage III to IVB diseases
received concurrent chemoradiation as mentioned followed by adjuvant chemotherapy with
cisplatin 80mg/m2 on day 1 and 5-FU 1000mg/m2 from day 1 to 4 every 4 weeks for 3 more
cycles starting 4 weeks after completion of IMRT, according to Intergroup 0099 trial [3, 19].
Some patients received 3 cycles of induction chemotherapy (cisplatin 100mg/m2 on day 1 and
5-FU 1000mg/m2 from day 1 to 5 every 3 weeks) before concurrent chemoradiation due to
close proximity of their tumors to the normal critical OARs including brainstem, spinal cord,
optic chiasm/nerves, etc, in an attempt for good tumor shrinkage so that a radical radiation
dose could be delivered to the tumors with relative sparing of these OARs.
The gross tumor volumes of both the primary tumor (GTV-P) and the radiologically
involved cervical nodes (GTV-N) were outlined on the planning CT images with the aid of co-
Fig 1. Computed tomography image showing the beam orientation and isodose distribution of a
9-field intensity-modulated radiation therapy (IMRT) plan for a patient with non-metastatic
nasopharyngeal carcinoma.
doi:10.1371/journal.pone.0157969.g001
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registered MRI images as we described before [20]. Subsequently clinical target volume (CTV-
70) and planning target volume containing CTV-70 with a 5mmmargin (PTV-70) were gener-
ated to take into account the microscopic disease spread, physiological body motions and set-
up errors respectively. Another CTV-66 encompassing the high risk areas including the poste-
rior half of the maxillary sinuses, nasal cavities, parapharyngeal spaces, styloid processes,
basiocciput, basisphenoid, clivus, foramina rotunda and ovale, pterygopalatine fossae, pterygo-
maxillary fissures, infra-orbital fissures, cavernous sinuses and level Ib and level V nodal sta-
tions was also contoured. A corresponding PTV-66 with a 3mmmargin encompassing CTV-
66 was created by boolean operations of the treatment planning system (Eclipse version 8.0,
USA) which was also used for IMRT planning. OARs included brainstem, spinal cord,
globes, optic nerves, optic chiasm, lenses, temporomandibular joints, temporal lobes, auditory
nerves, cochleae, mandible, oral cavity, larynx, parotid glands and the vestibules [20].
During IMRT optimization, the maximum dose of brainstem, optic nerves and chiasm must
be 54 Gy (allowing 0.1cc brainstem< 60Gy) and spinal cord 45Gy (allowing 0.1cc spinal
cord< 48Gy). Efforts were also made to limit mean dose of parotid glands to 26 Gy whenever
Table 1. Baseline patient characteristics of the 104 patients.
Characteristic N (%)
Median age in years (range) 53 (27–80)
Male/female 85 (81.7)/19 (18.3)
T-classiﬁcation
T1 24 (23.1)
T2 30 (28.8)
T3 39 (37.5)
T4 11 (10.6)
N-classiﬁcation
N0 26 (25.0)
N1 25 (24.0)
N2 41 (39.4)
N3a 6 (5.8)
N3b 6 (5.8)
Overall stage
I 12 (11.5)
II 20 (19.2)
III 50 (48.1)
IVA 10 (9.6)
IVB 12 (11.5)
IMRT alone 14 (13.5)
Concurrent chemoradiation
Concurrent chemoradiation alone 17 (16.3)
Induction chemotherapy then concurrent
chemoradiation
20 (19.2)
Concurrent chemotherapy then adjuvant
chemotherapy
53 (51.0)
PD-L1 expression level by immunohistochemistry
0 78 (75.0)
1+ 4 (3.8)
2+ 22 (21.2)
Abbreviations: IMRT, intensity-modulated radiation therapy; PD-L1, programmed death-ligand 1.
doi:10.1371/journal.pone.0157969.t001
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possible and dose to the lenses and temporal lobes as low as reasonably achieved without
compromising dose coverage to the PTVs.
A 9-field IMRT plan delivered by step-and-shoot technique was generated by Eclipse Treat-
ment Planning System version 8.9, Palo Alto, CA, USA) using Anisotropic Analytical Algo-
rithm (Fig 1). A total dose of 70 Gy and 66 Gy was prescribed to PTV-70 and PTV-66
respectively with simultaneous accelerated radiation therapy technique (SMART), as this has
been the standard IMRT prescriptions in our institution for the past 10 years [20]. All IMRT
plans fulfilled acceptance criteria with at least 95% of PTVs having received the prescribed
dose, the maximum dose of PTVs limited to 107% or below and the maximum dose of organs-
at-risk within tolerance limits according to International Commission on Radiation Units and
Measurements (ICRU) criteria and they were delivered by a 6MV linear accelerator (Varian
Medical Systems, Palo Alto, CA, USA). Positional verification with on-board imaging was per-
formed before IMRT commencement. It was repeated again daily immediately before the first
3 fractions of IMRT followed and then weekly afterwards during the whole course of IMRT, to
track any anteroposterior and lateral body displacements. All patients received regular clinical
follow up and imaging surveillance every 3 to 4 months for the first year after IMRT, then
every 6 months for the second year and yearly afterwards to exclude treatment failure and
relapse.
PD-L1 expression level by immunohisotchemistry
Immunohistochemical staining of 5μm sections from FFPE archived tissue of nasopharyngeal
biopsies or excision specimens of tumor was performed by in the diagnostic laboratory in Ana-
tomical Pathology Unit of our hospital with the antibody 1:200 anti-PD-L1 (E1L3N, Cell Sig-
naling Technology1, Danvers, MA, USA) using the standard protocol for routine diagnostic
specimens. Hematoxylin and eosin (H&E) sections were also reviewed for the presence of
tumors and TIL. Scoring of the intensity and percentage of tumor cells were done semi-quanti-
tatively. The intensity of immunohistochemical staining with PD-L1 was scored by a 3-point
scale. Score 0 meant minimal membrane staining with PD-L1 in less than 5% tumor cells, or
Fig 2. Immunohistochemical staining for PD-L1 in patients with non-metastastic nasopharyngeal carcinoma. (A) A patient whose tumor was scored 1
+ (weak to moderate membrane in about 5% of tumor cells) on immunohistochemical staining with PD-L1. (B) Another patient whose tumor was scored 2+
(moderate to strong membrane staining in more than 25% tumor cells) on immunohistochemical staining with PD-L1.
doi:10.1371/journal.pone.0157969.g002
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no staining with PD-L1 was identified. Score 1 (1+) indicated minimal to moderate membrane
staining with PD-L1 in between 5% to 24% tumor cells while score 2 (2+) comprises more posi-
tivity defined as at least 25% tumor cells demonstrating moderate to strong complete mem-
brane staining with PD-L1. The same scoring system also applied to PD-L1 expression for TILs
but their IHCs were reported separately from the IHCs for tumor cells.
Statistical analysis
Kaplan-Meier methods were employed for survival studies. Log-rank tests were used compari-
son of survival outcomes among patients with different stages of NPC and different expression
levels of PD-L1 as defined above. Cox proportional hazard models with univariable and multi-
variable analyses were performed to identify prognostic factors of survival endpoints including
locoregional failure-free survival (LRFFS), progression-free survival (PFS), distant metastasis-
free survival (DMFS) and overall survival (OS) with age as continuous covariate and sex, use of
Table 2. Comparison of baseline clinical parameters of patients stratified by the levels of PD-L1
expression with immunohistochemical staining (0 or 1+ versus 2+).
IHC 0 or 1+ IHC 2+ P
Median age in years
(range)
52.5 (27–80) 53.5 (30–75) 0.855
Male/female 66/16 19/3 0.527
T-classiﬁcation 0.523
T1 19 5
T2 21 9
T3 33 6
T4 9 2
N-classiﬁcation 0.117
N0 23 3
N1 22 3
N2 29 12
N3a 3 3
N3b 5 1
Overall stage 0.865
I 10 2
II 16 4
III 40 10
IVA 8 2
IVB 8 4
IMRT alone 12 2 0.499
Concurrent
chemoradiation
0.793
Concurrent
chemoradiation alone
13 4
Induction chemotherapy
then concurrent
chemoradiation
16 4
Concurrent
chemotherapy then
adjuvant
chemotherapy
41 12
Abbreviations: IHC, immunohistochemical staining; IMRT, intensity-modulated radiation therapy.
doi:10.1371/journal.pone.0157969.t002
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IMRT alone, use of concurrent chemoradiation alone, use of induction chemotherapy followed
by concurrent chemoradiation, use of concurrent chemoradiation followed by adjuvant che-
motherapy, T-classification (T1/T2 vs. T3/T4), N-classification (N0/N1 vs. N2/N3), overall
stage (I/II vs. III/IVA-B), expression levels of PD-L1 as categorical covariates. LRFFS was calcu-
lated from the starting date of IMRT to the date of occurrence of locoregional recurrence or
death from any cause. PFS started from date of commencement of IMRT to the date of disease
progression or death from any cause. DMFS was calculated from the starting date of IMRT to
the date of occurrence of distant metastasis or death from any cause. OS was defined from the
date of commencement of IMRT to the date of death from any cause. Receiver-operating char-
acteristic (ROC) curves were constructed for the performance of the cut-off value of IHC scores
of PD-L1 expression on the survival endpoints. Statistical significance was defined as P< 0.05
(two-sided). All statistical analyses were performed by Statistical Package for Social Sciences
(SPSS) version 20.0.
Results
Out of 146 consecutive patients with non-metastatic NPC treated with radical IMRT, only 104
patients were eligible with adequate archived tumor samples for IHC staining and subsequent
analysis. The baseline characteristics of these 104 patients were displayed in Table 1. Fourteen
patients (13.5%) received IMRT alone because of early-stage (stage I and II) diseases, advanced
age or significant medical comorbidities. Seventeen patients (16.3%) received concurrent che-
moradiation alone for their bulky stage II disease. Twenty patients (19.2%) received induction
chemotherapy followed by concurrent chemoradiation at the discretion of treating radiation
oncologists because of the close proximity of their primary tumors to the critical OARs. The
remaining 53 patients (51.0%) received concurrent chemoradiation followed by adjuvant che-
motherapy. All patients completed IMRT without suspension.
After a median follow-up duration of 7.6 years (5.7–10.8 years), 21 (20.2%), 19 (18.3%) and
31 (29.8%) patients suffered from locoregional failure, distant metastases and overall disease
progression respectively and 31 (29.8%) patients died during the study period. The median
LRFFS, PFS, DMFS and OS were not reached. The mean LRFFS, PFS, DMFS and OS were 78.5,
Fig 3. Micrograph showing the absence of immunohistochemical staining for PD-L1 in tumor-infiltrating lymphocytes. (A) Low-power field. (B) High-
power field despite strong immune-positivity to PD-L1 in the adjacent tumor cells.
doi:10.1371/journal.pone.0157969.g003
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71.7, 94.0 and 89.4 months respectively. The 5-year corresponding rates were 79.9%, 71.4%,
85.7% and 81.7% respectively.
Patterns of IHC staining with PD-L1
Seventy-eight patients (75.0%) had no membrane staining with PD-L1 for their tumor cells.
Four (3.8%) and 22 (21.2%) patients had IHC 1+ and IHC 2+ for their tumor cells respectively
(Fig 2). The baseline clinical demographics between these 2 groups of patients were shown,
without any statistically significant differences noted (Table 2). This observation suggested that
PD-L1 expression might not be common in NPC tumor cells. However, once the gene was
induced, expression level can be prominent and in significant proportion of the tumor. There-
fore we grouped IHC 0 or 1+ as one group against IHC 2+ in our subsequent univariable and
multivariable analyses as we believed that tumour cells with IHC 1+ (minimal to moderate
membrane staining) behaved similarly as those with IHC 0. Interestingly, although there were
many TILs associated with the tumor cells, PD-L1 was only expressed in these tumor-
Fig 4. Kaplan-Meier curves stratified by the patterns of immunohistochemical staining for PD-L1 (2+ vs 0 or 1+). (A) Loco-regional failure-free
survival. (B) Progression-free survival. (C) Distant metastasis failure-free survival. (D) Overall survival.
doi:10.1371/journal.pone.0157969.g004
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Fig 5. Receiver operating characteristics curve showing the performance of PD-L1 IHC 2+ as cut-off
for locoregional progression of patients with non-metastatic NPC treated with radical intensity-
modulated radiation with or without adjunct chemotherapy.
doi:10.1371/journal.pone.0157969.g005
Fig 6. Receiver operating characteristics curve showing the performance of PD-L1 IHC 2+ as cut-off
for overall progression of patients with non-metastatic NPC treated with radical intensity-modulated
radiation with or without adjunct chemotherapy.
doi:10.1371/journal.pone.0157969.g006
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associated lymphoid cells in a scattered manner. None of the tumors had more than 10% of
intimately associated lymphocytes with discernible PD-L1 staining and thus all TILs scored 0
for their PD-L1 expression (Fig 3).
Subgroup analyses revealed that patients whose tumors exhibited PD-L1 IHC 2+ enjoyed a
significantly longer LRFFS (5-year 100%, hazard ratio [HR], 0.159, 95% confidence interval
[CI], 0.021–0.988; P = 0.042) compared to those whose tumors were PD-L1 IHC 0 or 1+ only
(5-year 74.4%) (Fig 4A). Similarly, marginally longer PFS was also seen in those whose tumors
exhibited PD-L1 IHC 2+ (5-year 95.0%, HR, 0.351, 95% CI, 0.108–0.999; P = 0.067) compared
to those whose tumors was PD-L1 0 or 1+ only (5-year 65.2%) (Fig 4B). No significant dif-
ferences in DMFS and OS were noticed between patients whose tumors exhibited PD-L1 IHC
2+ and the rest whose tumors exhibited PD-L1 IHC 0 or 1+ only (Fig 4C and 4D), despite a
numerical advantage for patients whose tumors demonstrating PD-L1 IHC 2+. ROC analysis
showed that the area-under-the-curve (AUC) values for locoregional progression and overall
progression was 0.613 (95% CI, 0.479–0.726, P = 0.048) and 0.590 (95% CI, 0.467–0.697,
P = 0.059) respectively by using IHC 2+ as the cutoff (Figs 5 and 6).
Univariable and multivariable analyses
Univariable and multivariable analyses were performed for LRFFS and PFS (Tables 3 and 4) as
well as DMFS and OS (Tables 5 and 6). IMRT alone versus concurrent chemoradiation was not
prognostic of any survival endpoint. While T-classification, induction chemotherapy followed
Table 3. Univariable andmultivariable analysis for locoregional failure-free survival.
Univariable analysis Multivariable analysisa
HR 95% CI P HR 95% CI P
Age 0.976 0.940–1.014 0.216 ND
Sex (male as
reference)
1.328 0.391–4.512 0.650 ND
T-classiﬁcation
T1/T2 vs. T3/T4 0.388 0.156–0.964 0.042 0.465 0.268–1.254 0.162
N-classiﬁcation
N0N1 vs. N2N3 0.737 0.310–1.749 0.488 ND
Overall stage
I/II vs. III/IVA-B 0.307 0.090–1.043 0.058 0.415 0.125–1.297 0.161
IMRT alone 3.546 0.476–26.316 0.217 ND
Concurrent
chemoradiation
0.456 0.106–1.961 0.291 ND
Induction
chemotherapy then
concurrent
chemoradiation
0.324 0.134–0.785 0.023 0.337 0.136–0.802 0.029
Concurrent
chemoradiation
then adjuvant
chemotherapy
1.069 0.454–2.518 0.879 ND
PD-L1 expression
level
PD-L1 1+ 0.268 0.062–1.152 0.077 0.278 0.061–1.149 0.060
PD-L1 2+ 0.162 0.022–1.000 0.042 0.159 0.021–0.988 0.014
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; ND, not done; PD-L1, programmed death-ligand 1.
aOnly covariates found signiﬁcant (P < 0.1) in the univariable analysis were considered in the multivariable analysis.
doi:10.1371/journal.pone.0157969.t003
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by concurrent chemoradiation, PD-L1 IHC 0 or 1+ and PD-L1 IHC 2+ were significant in uni-
variable analysis, only induction chemotherapy followed by concurrent chemoradiation
(P = 0.029) and PD-L1 IHC 2+ (P = 0.014) were independently and significantly prognostic of
LRFFS in multivariable analysis. For PFS, T-classification, induction chemotherapy followed
by concurrent chemoradiation and PD-L1 IHC 0 or 1+ and PD-L1 IHC 2+ were significant in
univariable analysis. However only T-classification (P = 0.019) and PD-L1 IHC 2+ (P = 0.045)
were significant as independent prognostic factors in the subsequent multivariable analysis.
For DMFS, only induction chemotherapy followed by concurrent chemoradiation was prog-
nostic in both univariable (P = 0.003) and multivariable analyses (P = 0.003). Only T-classifica-
tion was prognostic of OS in both univariable (P = 0.031) and multivariable analyses
(P = 0.026). Besides, no statistical analysis was performed for the correlation between PD-L1
expression of TIL and each survival endpoint because no definite PD-L1 staining was observed
for all TILs.
Discussion
In our study, PD-L1 was overexpressed in 25% (26 of 104 patients) of NPC patients and
21.2% of our patients whose tumors were IHC 2+ with PD-L1. Our result revealed that PD-L1
IHC 2+ was associated with better LRRFS and PFS. These advantages of PD-L1 expressed
tumors have been observed in stage I resected pulmonary adenocarcinoma which was associ-
ated with a better relapse-free survival [21]. In a previous study by Zhang et al, PD-1 alone, an
Table 4. Univariable andmultivariable analyses for progression-free survival.
Univariable analysis Multivariable analysisa
HR 95% CI P HR 95% CI P
Age 0.992 0.963–1.022 0.606 ND
Sex (male as
reference)
0.899 0.368–2.194 0.815 ND
T-classiﬁcation
T1/T2 vs. T3/T4 0.357 0.168–0.759 0.007 0.363 0.170–0.761 0.009
N-classiﬁcation
N0/N1 vs. N2/N3 0.708 0.347–1.446 0.343 ND
Overall stage
I/II vs. III/IVA-B 0.437 0.179–1.066 0.069 0.456 0.176–1.131 0.110
IMRT alone 2.632 0.628–10.989 0.186 ND
Concurrent
chemoradiation
0.643 0.225–1.838 0.410 ND
Induction
chemotherapy then
concurrent
chemoradiation
0.335 0.160–0.702 0.014 0.401 0.205–1.563 0.254
Concurrent
chemoradiation
then adjuvant
chemotherapy
0.820 0.404–1.664 0.582 ND
PD-L1 expression
level
PD-L1 1+ 0.386 0.135–1.104 0.076 0.398 0.140–1.108 0.056
PD-L1 2+ 0.346 0.105–1.010 0.067 0.351 0.108–0.999 0.045
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; ND, not done; PD-L1, programmed death-ligand 1.
aOnly covariates found signiﬁcant (P < 0.1) in the univariable analysis were considered in the multivariable analysis.
doi:10.1371/journal.pone.0157969.t004
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immune checkpoint expressed on the surface of T-lymphocytes upon activation, or in combi-
nation with PD-L1, was associated with a worse disease-free survival in NPC patients [22].
However this study also included stage IVC metastatic diseases and their patients were all
treated with conventional radiation technique. As the latter radiation modality was considered
outdated in the modern era of IMRT or other precision radiation technique, their conclusion
on the prognostic significance of PD-L1 expression was not directly comparable to our current
observations. Our study, on the contrary, recruited a more representative population of non-
metastatic NPC patients who were all treated with standard dosing schedules of IMRT. On the
other hand, other clinical parameters for instance IMRT alone versus concurrent chemoradia-
tion and the sequence of chemotherapy (except induction chemotherapy followed by concur-
rent chemoradiation which was prognostic of LRRFS and DMFS and advanced T-classification
which was prognostic of PFS and OS) were not prognostic factors of the survival endpoints.
The role of TILs on survival outcome should be further explored. Hsu et al demonstrated
that the presence of PD-1 expressing TILs was prognostic of locoregional relapse-free survival,
disease-free survival and OS [23]. However only 46 patients were analyzed in their study,
which were fewer than our study population. In addition, the definition of PD-1 positivity in
both the tumor cells and TILs was not clearly stated. Besides, the chosen cut-off value of
median PD-1 expression rate set at 27.8% was rather arbitrary and haphazard without detailed
explanation. Instead, all TILs virtually did not express PD-L1 in our study and their prognostic
role needs further investigation in future studies.
Table 5. Univariable andmultivariable analysis for distant metastasis-free survival.
Univariable analysis Multivariable analysisa
HR 95% CI P HR 95% CI P
Age 1.006 0.968–1.045 0.775 ND
Sex (male as
reference)
0.676 0.241–1.896 0.457 ND
T-classiﬁcation
T1/T2 vs. T3/T4 0.392 0.148–1.034 0.058 0.495 0.183–1.335 0.165
N-classiﬁcation
N0N1 vs. N2/N3 0.486 0.188–1.255 0.136 ND
Overall stage
I/II vs. III/IVA-B 0.550 0.181–1.670 0.291 ND
IMRT alone 2.899 0.386–21.739 0.301 ND
Concurrent
chemoradiation
1.060 0.304–3.689 0.927 ND
Induction
chemotherapy then
concurrent
chemoradiation
0.217 0.083–0.568 0.003 0.219 0.080–0.565 0.003
Concurrent
chemoradiation
then adjuvant
chemotherapy
0.472 0.177–1.263 0.135 ND
PD-L1 expression
level
PD-L1 1+ 0.533 0.155–1.835 0.319 ND
PD-L1 2+ 0.782 0.225–2.725 0.700 ND
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; ND, not done; PD-L1, programmed death-ligand 1.
aOnly covariates found signiﬁcant (P < 0.1) in the univariable analysis were considered in the multivariable analysis.
doi:10.1371/journal.pone.0157969.t005
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The prognostic role of PD-L1 in various types of malignancies remains to be deciphered.
Though most studies delineated negative correlation of PD-L1 expression with survival in gen-
eral [24–28], other studies in specific tumors such as colorectal cancer, non-small cell lung can-
cer and melanoma demonstrated more favorable correlations between its expression and
survival [29–32]. This reflected that the interaction between PD-L1 expression and host
immune responses differs among various types of cancer. In fact, PD-L1 expression is not
directly proportional to tumor immune evasion and it may just signify an ongoing anti-tumor
immune response that leads to production of interferon-γ and other inflammatory markers
[32]. The tumor microenvironment may be even more complication in virus-associated tumors
like NPC, as neoantigens associated with infection by these tumor-promoting viruses may give
rise to inflammatory responses leading to PD-L1 expression [29,33]. In addition, whether it
has another role on radiosensitivity or radioresistance for head and neck cancer and NPC war-
rants further studies for confirmation.
The scoring system of IHC for PD-L1 has yet to be defined and it may vary for different
types of malignancies. Traditionally, the median value of the percentage of tumor cells positive
for PD-L1 in order to balance the patient groups is most often used. Alternatively, the semi-
quantitative H-score, obtained by multiplying the percentage of positively-stained tumor cells
and the intensity of staining was also commonly used. In addition, definition of staining posi-
tivity (for example cell surface versus cytoplasmic expression, by tumor cells only or by other
cells in the tumor milieu, percentage of stained cells regarded as positive) has not reached a
Table 6. Univariable andmultivariable analyses for overall survival.
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Age 1.068 0.968–1.100 0.975 ND
Sex (male as
reference)
0.985 0.398–2.439 0.974 ND
T-classiﬁcation
T1/T2 vs. T3/T4 0.432 0.201–0.928 0.031 0.429 0.211–0.919 0.026
N-classiﬁcation
N0/N1 vs. N2/N3 0.810 0.393–1.667 0.567 ND
Overall stage
I/II vs. III/IVA-B 0.428 0.162–1.125 0.085 0.452 0.189–1.273 0.145
IMRT alone 2.101 0.499–8.850 0.311 ND
Concurrent
chemoradiation
0.534 0.161–1.767 0.304 ND
Induction
chemotherapy then
concurrent
chemoradiation
0.965 0.365–2.551 0.943 ND
Concurrent
chemoradiation
then adjuvant
chemotherapy
0.532 0.245–1.152 0.109 ND
PD-L1 expression
level
PD-L1 1+ 0.576 0.220–1.508 0.261 ND
PD-L1 2+ 0.627 0.217–1.812 0.388 ND
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; ND, not done; PD-L1, programmed death-ligand 1.
aOnly covariates found signiﬁcant (P < 0.1) in the univariable analysis were considered in the multivariable analysis.
doi:10.1371/journal.pone.0157969.t006
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unanimous consensus. For instance, positivity defined as 5% tumor cells positively stained
with PD-L1 has recently gained popularity in lung cancer studies [21,34]. In fact even for phase
III randomized-controlled trials using the FDA-approved pembrolizumab and nivolumab for
advanced non-small cell lung cancer, the cutoffs (1% and 50% for pembrolizumab in their
KEYNOTE-001) and (1%, 5% and 10% for nivolumab in their CheckMate 017 trial) chosen
were arbitrary at the drug sponsor’s discretion without detailed explanation and their subse-
quently statistical analyses were also exploratory without detailed elaboration [35–37]. The
percentage of PD-L1 positivity was also heavily dependent on the performance of the test kits
and antibodies, the number of slides reviewed and the amount of tumor cells and TIL retrieved
during micro-dissection of the specimens which can be highly operator dependent. As a result,
we thought that choosing 5% and 25% (instead of 1% and 5% in the drug-sponsored trials) as
cutoffs were less susceptible to the effect of sampling size and sampling errors of the tumor
cells retrieved during micro-dissection. The general impression of PD-L1 expression studies in
various types of tumors suggested that different tumors would have different scoring systems.
This might include not just differences in the percentage and intensity of PD-L1 expression in
tumor cells to be considered positive or negative IHC results, but might extend to include
PD-L1 expression in the TIL or even the stromal cells. In the context of immune checkpoints
and immunotherapy, these observations suggested that consideration of the overall tumor and
microenvironment should be important in predicting the success of immunotherapy. Ulti-
mately, it would be most desirable if the definition and scoring system for PD-L1 IHC correlate
with treatment response and survival.
Conclusion
We conclude that PD-L1 expression level can be used as a prognostic factor of LRRFS and PFS
in non-metastatic NPC patients treated with radical IMRT. This has provided insight in
designing immunotherapy targeting the PD-L1 pathway in combination with IMRT in the
future, which should be validated in prospective randomized studies.
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